Articles written by Vandana Singh - Benzinga

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

|Coya Therapeutics' Phase 2 study shows monthly LD IL-2 improves cognitive scores and reduces inflammation in Alzheimer's patients, with no serious adverse events.

Labcorp Q4 Earnings: Revenue And EPS Beat, Expects Strong 2025 Growth, Analyst Reiterates Outperform On Stable 2025 Outlook

|Labcorp's Q4 EPS of $3.45 topped estimates, with sales rising 9.8% to $3.33 billion. 2025 guidance points to continued growth in diagnostics and biopharma.

Why Is Zimmer Biomet Stock Trading Lower On Thursday?

|Zimmer Biomet beat Q4 estimates with $2.02 billion in sales and $2.31 EPS.

Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies

|Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA submission set for Q2 2025.

IQVIA Delivers Solid Q4 Growth Despite 'Choppy' Market Conditions

|IQVIA reaffirms its 2025 outlook, projecting up to $16.13 billion in revenue and EPS of $11.70-$12.10. Strong TAS growth and solid R&DS bookings fuel confidence.

Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business

|Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.

Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts

|Bristol Myers Squibb beat Q4 estimates with $12.34 billion revenue and $1.67 EPS. 2025 guidance lags expectations amid generic headwinds and cost-saving plans.

AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China

|AstraZeneca's Q4 revenue beat estimates at $14.89 billion, with strong oncology sales. China sales dipped 1%, while FY25 guidance forecasts solid growth.

EXCLUSIVE: Intelligent Bio Solutions Expects To Record Increased Profitability In Q2 On Higher-Margin Sales

|Intelligent Bio Solutions reports rising sales and profit margins, driven by recurring revenue from cartridge sales and global expansion through key partnerships.

Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines

|Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.

What To Expect When Eli Lilly Reports Q4 Earnings On Thursday?

|Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.

Analysts Defend Merck Amid Investor Concerns Over Weak Guidance

|Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a lower-than-expected 2025 outlook.

Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead

|Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

Cencora Q1 Earnings: Revenue And EPS Beat On Strong Push From Obesity Drugs, Specialty Medicines

|Cencora posted Q1 sales of $81.5 billion, exceeding forecasts, with strong GLP-1 drug sales. Adjusted EPS beat estimates, and FY25 guidance was raised.

Aurora Cannabis Stock Jumps On 'Record-Breaking' Q3 Earnings

|Aurora Cannabis posted Q3 FY25 net revenue of CA$88.2 million, driven by medical cannabis and plant propagation growth, with adjusted EBITDA rising 316% to CA$23.1 million.

Boston Scientific Clocks 22% Jump In Q4 Sales On Strong Heart Devices, Profit And Guidance Exceeds Expectations

|Boston Scientific posted Q4 revenue of $4.56 billion, surpassing estimates. The company forecasts 2025 sales growth of up to 14.5% and EPS of $2.80-$2.87.

EXCLUSIVE: Isreal-Based Inspira Technologies Integrates New Oxygenation Indicator Into HYLA Blood Sensor To Enhance Critical Care Monitoring

|Inspira Technologies integrates an AI-powered oxygenation indicator into its HYLA sensor, aiming to enhance real-time monitoring and critical care capabilities.

GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 Billion

|GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company announced a $2.5 billion share buyback plan.

Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026

|Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in 2025, with results expected in Q1.

Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease

|Cumberland Pharmaceuticals' Phase 2 trial shows ifetroban improves heart function in Duchenne muscular dystrophy patients.